About this trial
This study aims to compare the effects of intranasal dexmedetomidine and oral midazolam as premedication in pediatric patients undergoing elective inguinal and urological surgery under general anesthesia.
Premedication plays a critical role in reducing preoperative anxiety, facilitating parent-child separation, and improving cooperation during anesthesia induction in pediatric patients. While oral midazolam is widely used, it has several limitations, including variable bioavailability and the risk of paradoxical reactions. Intranasal dexmedetomidine has emerged as a promising alternative due to its sedative, anxiolytic, and minimal respiratory depressant effects.
In this prospective, randomized, double-blind, controlled study, patients aged 2-10 years will be assigned to receive either intranasal dexmedetomidine or oral midazolam prior to anesthesia induction. The primary outcome is the proportion of patients achieving adequate sedation at induction, defined as a Ramsay Sedation Score (RSS) ≥2.
Secondary outcomes include perioperative hemodynamic stability, parent-child separation anxiety, mask acceptance during induction, postoperative emergence agitation, recovery time, and the need for rescue sedation.
Eligibility criteria
Qualifiers
Pediatric patients aged 2-10 years
ASA physical status I-II
Scheduled for elective inguinal or urological surgery under general anesthesia
Both male and female patients
Disqualifiers
Known allergy or hypersensitivity to dexmedetomidine or midazolam
Presence of significant systemic disease or organ dysfunction
Cardiac arrhythmia or congenital heart disease
Neurological or behavioral disorders, including developmental delay
Trial design
Treatments tested in this trial
- Dexmedetomidine
- Midazolam